RWDD4

Across TCGA pan-cancer cohorts, RWDD4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RWDD4 data layer compared with 24 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RWDD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RWDD4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, LUAD, and SARC are the cancer types where RWDD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
LUAD	OS	Median	All	0.313	0.812	.015	9	view →
SARC	OS	Median	All	0.162	0.767	.002	6	view →
UCEC	DFS	Median	All	1.000	0.631	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RWDD4–OV (OS)

Open the OV breakdown →